Trial Name
and Design

Cell Line

Sample Size
(n)

Cell Dose

Days to Admin Post MI

Route of Admin

Imaging
Modality

Primary End Point

LEUVEN-AMI [47]
(RCT 2006)

BMC

67

3.0 ± 1.3 × 108

<24 hours

IC

MRI

•No increase in EF over control  (At 4 months)
•Possible decrease in infarct size

ASTAMI [48]
(RCT 2006)

BMC

100

0.68 × 108 (median)

6 ± 1

IC

SPECT

•No increase in EF over control (At 6 months)

REGENT [38]
(RCT 2009)

BMC or
CD34/CXCR4

200

BMC: 1.78 × 108 (median)
CD34/CXCR4: 0.019 × 108 (median)

3-12

IC

MRI

•No increase in EF over control

HEBE [39]
(RCT 2010)

BMC or
mPBC

200

BMC: 3 ± 1.6 × 108
mPBC: 2.9 ± 1.4 × 108

3-8

IC

MRI

•No increase in EF over control (At 4 months)

BONAMI [49] (RCT 2009)

BMC

101

0.98 ± 0.09 × 108

9.3 ± 1.7

IC

SPECT
RNA
MRI
ECHO

•No increase in EF over control
•No decrease in infarct size (At 3 months)

CADUCEUS [46]
(RCT 2012)

CDC

31

12.5-25 × 106

1.5–3 mths

IC

MRI

•No increase in EF over control  (At 6 months)

All values are mean ± SD unless stated
Table 3: Abbreviations: ASTAMI Trial: Autologous Stem cell Transplantation in Acute Myocardial Infarction Trial; REGENT Trial: Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction Trial; HEBE Trial: Intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary PCI Trial; BONAMI Trial: Bone Marrow in Acute Myocardial Infarction Trial; CADUCEUS Trial: Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction trial; MRI: Magnetic resonance imaging, SPECT: Single Photon Emission Computed Tomography; CPC: Cardiac progenitor cell; LVESV: Left ventricular end systolic volume; PBC: Peripheral blood cell; RNA: Radionuclide angiography, CDC: Cardiosphere derived cell.